Nootropic
Sunifiram
SaveA synthetic piperazine-derived AMPAkine structurally related to piracetam but reportedly 1000x more potent by weight in rodent models. Never tested in human clinical trials.
Quick verdict
Potent in rodent memory models at microgram doses, but zero human data. The gulf between animal AMPAkine research and safe human use is vast.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Rodent studies show memory enhancement via AMPA receptor potentiation, LTP facilitation, and CaMKII/PKC activation. Active at 0.001–1 mg/kg in mice. No human pharmacokinetic, efficacy, or safety data.
Benefits
- Potent memory enhancement in rodent models at low doses
- Facilitates long-term potentiation in hippocampal slices
Dosage notes
No validated human dose. Self-experimenters report 4–10 mg sublingually.
Side effects
- Unknown — no human data
- Theoretical seizure risk
Who should be cautious
No human safety data. AMPAkine overstimulation carries theoretical seizure risk. Not approved for any use.
What this page cannot tell you
Extreme potency in rodents does not guarantee efficacy or safety in humans. Self-experimentation at this level carries real risk.
Leaderboard scores
- Memory20
- Focus15
Write a review
Sign in to write a review.